Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
Urbonas V., Schadendorf D., Zimmer L., Danson S., Marshall E., Corrie P., Wheater M., Plummer E., Mauch C., Scudder C., Goff M., Love SB., Mohammed SB., Middleton MR.